Bimonte Sabrina, Cascella Marco, Schiavone Vincenzo, Mehrabi-Kermani Farrokh, Cuomo Arturo
Division of Anesthesia and Pain Medicine, Istituto Nazionale Tumori - IRCCS - "Fondazione G. Pascale", Naples, Italy.
Division of Anesthesia and Intensive Care, Hospital "Pineta Grande", Castel Volturno, Caserta, Italy.
Drug Des Devel Ther. 2017 Sep 13;11:2737-2742. doi: 10.2147/DDDT.S142475. eCollection 2017.
Neuropathic pain (NP) is a complex and chronic disease caused by lesions or defects of the somatosensory nervous system. The treatments normally used for managing NP usually lack efficacy. Several animal models of NP have been engineered in order to understand the molecular mechanisms underlying NP and to find alternative molecules to use as new therapeutic agents. Preclinical in vivo studies identified the epigallocatechin-3-gallate (EGCG), a main active component of green tea (), as a possible therapeutic molecule for NP treatment due to its anti-inflammatory and antioxidant properties. Interestingly, it has been shown that EGCG reduced bone cancer pain. The purpose of this article is to discuss the potential use of EGCG for control and treatment of NP, by reviewing the preclinical studies reported in the literature and by shedding light on the potential schemes based on EGCG's application in clinical practices.
神经性疼痛（NP）是一种由躯体感觉神经系统损伤或缺陷引起的复杂慢性疾病。通常用于治疗NP的方法往往缺乏疗效。为了了解NP的分子机制并寻找用作新治疗药物的替代分子，已经构建了几种NP动物模型。临床前体内研究确定表没食子儿茶素-3-没食子酸酯（EGCG），绿茶的主要活性成分，由于其抗炎和抗氧化特性，可能是治疗NP的治疗分子。有趣的是，已经表明EGCG可减轻骨癌疼痛。本文的目的是通过回顾文献中报道的临床前研究，并阐明基于EGCG在临床实践中的应用的潜在方案，来讨论EGCG在控制和治疗NP方面的潜在用途。
